Drug Profile


Alternative Names: Anti-EphA3 MAb; Anti-EphA3 monoclonal antibody; Humaneered antibody; IgG1-kappa antibody; IgG1K antibody; KB-004

Latest Information Update: 27 Nov 2015

Price : $50

At a glance

  • Originator Ludwig Institute for Cancer Research
  • Developer KaloBios Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action EphA3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes; Myelofibrosis

Most Recent Events

  • 26 Nov 2015 Phase-II clinical trials in Acute myeloid leukaemia in Australia, USA (IV)
  • 26 Nov 2015 Phase-II clinical trials in Myelodysplastic syndromes in Australia, USA (IV)
  • 26 Nov 2015 Phase-II clinical trials in Myelofibrosis in Australia, USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top